KMDA Kamada Ltd

Exhibit 99.1

 

Kamada Reports Strong Second Quarter and First Half 2024 Financial Results with Year-Over-Year 6-Month Top-Line Growth of 18% and a 68% Increase in Profitability

 

●	Revenues for Second Quarter of 2024 were $42.5 Million, up 13% Year-over-Year; First Half 2024 Total Revenues were $80.2 Million, up 18% Year-over-Year

 

●	Second Quarter 2024 Adjusted EBITDA of $9.1 Million, Representing 51% Increase Year-over-Year; First Half 2024 Adjusted EBITDA of $16.6 Million, up 68% Year-over-Year

 

●	Robust First Half 2024 Performance and Expectation for Similar Cadence of Financial Results for Second Half of the Year Supports Reiteration of Full-Year Revenue Guidance of $158 Million-$162 Million and Adjusted EBITDA of $28 Million-$32 Million

 

●	Conference Call and Live Webcast Today at 8:30 AM ET

 

REHOVOT, Israel, and Hoboken, NJ – August 14, 2024 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three and six months ended June 30, 2024.

 

“Our strong financial performance is indicative of the successful execution of our growth strategy as we continue to effectively leverage our multiple diverse commercial catalysts, including our six FDA-approved products,” said Amir London, Kamada’s Chief Executive Officer. “With total revenues for the first half of 2024 of $80.2 million, which represents year-over-year growth of 18%, adjusted EBITDA of $16.6 million, up 68% year-over-year and representing a 21% margin of revenues, we achieved the top- and bottom-line profitable growth anticipated in our business. In addition, during the first six months of the year, we generated $15.0 million of cash provided by operating activities, which demonstrates our ability to convert our reported adjusted EBITDA to operational cash flow.”

 

“Based on our continued strong performance and expectation for a cadence of financial results in the second half of 2024 consistent with those achieved in the first six months of the year, we are reiterating our full-year 2024 revenue guidance of $158 million to $162 million, and our adjusted EBITDA guidance of $28 million to $32 million. Importantly, we continue to pursue compelling new business development opportunities, leveraging our financial strength. These opportunities are expected to support continued growth at double-digit rates beyond 2024,” added Mr. London.

 

“Patient enrollment continues in our ongoing pivotal Phase 3 InnovAATe clinical trial for the inhaled Alpha-1 Antitrypsin therapy. Last quarter, we filed an IND amendment with the FDA consisting of a revised Statistical Analysis Plan (SAP) and study protocol, which, if approved, may allow for the acceleration of the program. We continue to expect further FDA feedback before the end of this year,” concluded Mr. London.

 

Financial Highlights for the Three Months Ended June 30, 2024

 

●

Total revenues were $42.5 million in the second quarter of 2024, a 13% increase from the prior year comparable quarter. The increase in revenues was primarily attributable to increased sales of KEDRAB due to increased market share in the U.S., as well as increased sales of CYTOGAM due to increased demand in the U.S. market.

 

●

Gross profit and gross margins were $19.0 million and 45%, respectively, in the second quarter of 2024, compared to $14.4 million and 39%, respectively, reported in the prior year comparable quarter.

 

 

●

Operating expenses, including R&D, S&M, G&A and other expenses, totaled $13.3 million in the second quarter of 2024, as compared to $11.8 million in the second quarter of 2023. The increase in operating expenses was primarily attributable to an increase in S&M costs associated with the marketing activities in the U.S., as well as increased R&D costs, primarily due to advancing the Inhaled AAT clinical trial.

 

●

Net income was $4.4 million, or $0.08 per share, in the second quarter of 2024, as compared to net income of $1.8 million, or $0.04 per share, in the second quarter of 2023.

 

●

Adjusted EBITDA, as detailed in the tables below, was $9.1 million in the second quarter of 2024, a 51% increase as compared to $6.0 million in the second quarter of 2023.

 

●

Cash provided by operating activities was $14.0 million in the second quarter of 2024, as compared to cash provided by operating activities of $1.8 million in the second quarter of 2023.

 

Financial Highlights for the Six Months Ended June 30, 2024

 

●

Total revenues for the first six months of 2024 were $80.2 million, an 18% increase from the $68.2 million generated in the first six months of 2023. The increase in revenues was primarily attributable to increased sales of KEDRAB due to increased market share in the U.S., as well as increased sales of CYTOGAM due to increased demand for the product in the U.S. market.

 

●

Gross profit and gross margins for the first six months of 2024 were $35.7 million and 45%, respectively, compared to $26.3 million and 39%, respectively, in the first half of 2023.

 

●

Operating expenses, including R&D, S&M, G&A and other expenses, totaled $26.0 million in the first six months of 2024, as compared to $23.4 million in the first half of 2023. The increase in operating expenses was primarily attributable to an increase in S&M costs associated with the marketing activities in the U.S., as well as increased R&D costs, primarily due to advancing the Inhaled AAT clinical trial.

 

●

Net profit for the first six months of 2024 was $6.8 million, or $0.12 per share, as compared to net profit of $3,000 or less than one cent per share, in the first six months of 2023.

 

●

Adjusted EBITDA, as detailed in the tables below, was $16.6 million in the first six months of 2024, a 68% increase as compared to $9.9 million in the first six months of 2023.

 

●

Cash provided by operating activities during the first six months of 2024 was approximately $15.0 million, as compared to cash used in operating activities of $1.0 million during the first six months of 2023. The change was correlated to the changes in the Company’s working capital.

 

Balance Sheet Highlights

 

As of June 30, 2024, the Company had cash, cash equivalents, and short-term investments of $56.5 million, as compared to $55.6 million on December 31, 2023.

 

Fiscal Year 2024 Guidance

 

Kamada continues to expect to generate fiscal year 2024 total revenues in the range of $158 million to $162 million, and adjusted EBITDA in the range of $28 million to $32 million, representing double digit top- and bottom-line growth year-over-year.

 

 

Conference Call

 

Kamada management will host an investment community conference call on Wednesday, August 14, 2024, at 8:30am Eastern Time to present the Company’s results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.) or 1-809-406-247 (from Israel) or 1-201-689-8263 (International) using conference ID 13747542. The call will also be webcast live on the Internet at:

 

https://viavid.webcasts.com/starthere.jsp?ei=1678713&tp_key=b3f21d48c3.

 

Non-IFRS financial measures

 

We present EBITDA and adjusted EBITDA because we use these non-IFRS financial measures to assess our operational performance, for financial and operational decision-making, and as a means to evaluate period-to-period comparisons on a consistent basis. Management believes these non-IFRS financial measures are useful to investors because: (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and provide investors with a meaningful perspective on the current underlying performance of the Company’s core ongoing operations; and (2) they exclude the impact of certain items that are not directly attributable to our core operating performance and that may obscure trends in the core operating performance of the business. Non-IFRS financial measures have limitations as an analytical tool and should not be considered in isolation from, or as a substitute for, our IFRS results. We expect to continue reporting non-IFRS financial measures, adjusting for the items described below, and we expect to continue to incur expenses similar to certain of the non-cash, non-IFRS adjustments described below. Accordingly, unless otherwise stated, the exclusion of these and other similar items in the presentation of non-IFRS financial measures should not be construed as an inference that these items are unusual, infrequent or non-recurring. EBITDA and adjusted EBITDA are not recognized terms under IFRS and do not purport to be an alternative to IFRS terms as an indicator of operating performance or any other IFRS measure. Moreover, because not all companies use identical measures and calculations, the presentation of EBITDA and adjusted EBITDA may not be comparable to other similarly titled measures of other companies. EBITDA is defined as net income (loss), plus income tax expense, plus or minus financial income or expenses, net, plus or minus income or expense in respect of securities measured at fair value, net, plus or minus income or expenses in respect of currency exchange differences and derivatives instruments, net, plus depreciation and amortization expense, whereas adjusted EBITDA is the EBITDA plus non-cash share-based compensation expenses and certain other costs.

 

For the projected 2024 adjusted EBITDA information presented herein, the Company is unable to provide a reconciliation of this forward measure to the most comparable IFRS financial measure because the information for these measures is dependent on future events, many of which are outside of the Company’s control. Additionally, estimating such forward-looking measures and providing a meaningful reconciliation consistent with the Company’s accounting policies for future periods is meaningfully difficult and requires a level of precision that is unavailable for these future periods and cannot be accomplished without unreasonable effort.  Forward-looking non-IFRS measures are estimated in a manner consistent with the relevant definitions and assumptions noted in the Company’s adjusted EBITDA for historical periods.

 

 

About Kamada

 

Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, focused on diseases of limited treatment alternatives. The Company is also advancing an innovative development pipeline targeting areas of significant unmet medical need. The Company’s strategy is focused on driving profitable growth from its significant commercial catalysts as well as its manufacturing and development expertise in the plasma-derived and biopharmaceutical fields. The Company’s commercial products portfolio includes six FDA approved plasma-derived biopharmaceutical products: CYTOGAM^®, KEDRAB^®, WINRHO SDF^®, VARIZIG^®, HEPAGAM B^® and GLASSIA^®, as well as KAMRAB^®, KAMRHO (D)^® and two types of equine-based anti-snake venom (ASV) products. The Company distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Argentina, Brazil, India, Australia and other countries in Latin America, Europe, the Middle East, and Asia. The Company leverages its expertise and presence in the Israeli market to distribute, for use in Israel, more than 25 pharmaceutical products that are supplied by international manufacturers. During recent years the Company added eleven biosimilar products to its Israeli distribution portfolio, which, subject to the European Medicines Agency (EMA) and the Israeli Ministry of Health approvals, are expected to be launched in Israel through 2028. The Company owns an FDA licensed plasma collection center in Beaumont, Texas, which currently specializes in the collection of hyper-immune plasma used in the manufacture of KAMRHO (D), KARAB and KEDRAB. In addition to the Company’s commercial operation, it invests in research and development of new product candidates. The Company’s leading investigational product is an inhaled AAT for the treatment of AAT deficiency, for which it is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares.

 

Cautionary Note Regarding Forward-Looking Statements

 

This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: 1) our expectation for a cadence of financial results in the second half of 2024 consistent with those achieved in the first six months of the year, 2) full-year revenue guidance to be $158 million-$162 million and adjusted EBITDA to be between $28 million-$32 million, 3) continuing to pursue compelling new business development opportunities, leveraging our financial strength and to support continued growth at double-digit rates beyond 2024, 4) continued patient enrollment in the ongoing pivotal Phase 3 InnovAATe clinical trial, and 5) our expectations to receive FDA feedback to the IND Amendment before the end of 2024, which, if approved, may allow for the acceleration of the InnovAATe program. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to the evolving nature of the conflicts in the Middle East and the impact of such conflicts in Israel, the Middle East and the rest of the world, the impact of these conflicts on market conditions and the general economic, industry and political conditions in Israel, the U.S. and globally, continuation of inbound and outbound international delivery routes, continued demand for Kamada’s products, financial conditions of the Company’s customer, suppliers and services providers, Kamada’s ability to integrate the new product portfolio into its current product portfolio, Kamada’s ability to grow the revenues of its new product portfolio, and leverage and expand its international distribution network, ability to reap the benefits of the acquisition of the plasma collection center, including the ability to open additional U.S. plasma centers, and acquisition of the FDA-approved plasma-derived hyperimmune commercial products, the ability to continue enrollment of the pivotal Phase 3 InnovAATe clinical trial, unexpected results of clinical studies, Kamada’s ability to manage operating expenses, additional competition in the markets that Kamada competes, regulatory delays, prevailing market conditions and the impact of general economic, industry or political conditions in the U.S., Israel or otherwise, and other risks detailed in Kamada’s filings with the U.S. Securities and Exchange Commission (the “SEC”) including those discussed in its most recent Annual Report on Form 20-F and in any subsequent reports on Form 6-K, each of which is on file or furnished with the SEC and available at the SEC’s website at www.sec.gov. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

 

CONTACTS:

 

Chaime Orlev

Chief Financial Officer

IR@kamada.com

 

Brian Ritchie

LifeSci Advisors, LLC

212-915-2578

britchie@LifeSciAdvisors.com

 

 

KAMADA LTD.

 

Condensed Consolidated Interim Statements of Financial Position

 

 

		As of								As of
		June 30,								December 31,
		2024				2023				2023
		Unaudited								Audited
Assets
Current Assets
Cash and cash equivalents		$	56,547			$	21,788			$	55,641
Trade receivables, net			26,228				24,581				19,877
Other accounts  receivables			4,940				3,077				5,965
Inventories			78,713				80,237				88,479
Total Current Assets			166,428				129,683				169,962
Non-Current Assets
Property, plant and equipment, net			31,971				26,936				28,224
Right-of-use assets			7,552				5,517				7,761
Intangible assets, Goodwill and other long-term assets			136,830				143,986				140,465
Contract assets			8,257				8,267				8,495
Total Non-Current Assets			184,610				184,706				184,945
Total Assets		$	351,038			$	314,389			$	354,907
Liabilities
Current Liabilities
Current maturities of bank loans		$	-			$	4,444			$	-
Current maturities of lease liabilities			1,494				1,063				1,384
Current maturities of other long term liabilities			12,610				25,077				14,996
Trade payables			19,532				27,969				24,804
Other accounts payables			7,233				7,235				8,261
Deferred revenues			27				38				148
Total Current Liabilities			40,896				65,826				49,593
Non-Current Liabilities
Bank loans			-				10,741				-
Lease liabilities			7,065				4,972				7,438
Contingent consideration			17,085				19,028				18,855
Other long-term liabilities			34,238				36,514				34,379
Employee benefit liabilities, net			602				556				621
Total Non-Current Liabilities			58,990				71,811				61,293
Shareholder’s Equity
Ordinary shares			15,023				11,737				15,021
Additional paid in capital  net			266,313				210,727				265,848
Capital reserve due to translation to presentation currency			(3,490	)			(3,490	)			(3,490	)
Capital reserve from hedges			(12	)			(67	)			140
Capital reserve from share-based payments			6,444				5,902				6,427
Capital reserve from employee benefits			283				424				275
Accumulated deficit			(33,409	)			(48,481	)			(40,200	)
Total Shareholder’s Equity			251,152				176,752				244,021
Total Liabilities and Shareholder’s Equity		$	351,038			$	314,389			$	354,907

 

 

KAMADA LTD.

 

Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income

 

		Six months period ended								Three months period ended								Year ended
		June 30,								June 30,								December 31,
		2024				2023				2024				2023				2023
		Unaudited								Unaudited								Audited
Revenues from proprietary products		$	72,904			$	55,001			$	39,146			$	30,940			$	115,458
Revenues from distribution			7,304				13,152				3,326				6,503				27,061
Total revenues			80,208				68,153				42,472				37,443				142,519
Cost of revenues from proprietary products			38,338				30,416				20,718				17,192				63,342
Cost of revenues from distribution			6,168				11,462				2,803				5,815				23,687
Total cost of revenues			44,506				41,878				23,521				23,007				87,029
Gross profit			35,702				26,275				18,951				14,436				55,490
Research and development expenses			9,098				7,514				4,803				4,283				13,933
Selling and marketing expenses			9,361				7,862				4,730				3,940				16,193
General and administrative expenses			7,564				6,902				3,778				3,484				14,381
Other expenses			-				1,077				-				98				919
Operating income (loss)			9,679				2,920				5,640				2,631				10,064
Financial income			788				25				508				-				588
Income (expenses) in respect of currency exchange differences and derivatives instruments, net			315				173				191				22				55
Financial Income (expense) in respect of contingent consideration and other long- term liabilities.			(3,550	)			(2,070	)			(1,705	)			(309	)			(980	)
Financial expenses			(304	)			(939	)			(145	)			(439	)			(1,298	)
Income (expense) before tax on income			6,928				109				4,489				1,905				8,429
Taxes on income			137				106				63				93				145
Net Income (loss)		$	6,791			$	3			$	4,426			$	1,812			$	8,284
Other Comprehensive Income (loss) :
Amounts that will be or that have been reclassified to profit or loss when specific conditions are met
Gain (loss) from securities measured at fair value through other comprehensive income
Gain (loss) on cash flow hedges			(95	)			(244	)			(24	)			(88	)			(186	)
Net amounts transferred to the statement of profit or loss for cash flow hedges			(57	)			265				-				120				414
Items that will not be reclassified to profit or loss in subsequent periods:
Remeasurement gain (loss) from defined benefit plan			8				76				1				(115	)			(73	)
Total comprehensive income (loss)		$	6,647			$	100			$	4,403			$	1,729			$	8,439
Earnings per share attributable to equity holders of the Company:
Basic net earnings per share			0.12			$	0.00			$	0.08			$	0.04			$	0.17
Diluted net earnings per share			0.12			$	0.00			$	0.08			$	0.04			$	0.15

 

 

KAMADA LTD.

 

Condensed Consolidated Interim Statements of Cash Flows

 

		Six months period Ended								Three months period Ended								Year Ended
		June, 30								June, 30								December 31,
		2024				2023				2024				2023				2023
		Unaudited																Audited
		U.S Dollars In thousands
Cash Flows from Operating Activities
Net income		$	6,791			$	3			$	4,426			$	1,812			$	8,284
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Adjustments to the profit or loss items:
Depreciation and impairment			6,466				6,327				3,229				3,204				12,714
Financial expenses (income), net			2,751				2,811				1,151				726				1,635
Cost of share-based payment			476				629				235				214				1,314
Taxes on income			137				106				63				93				145
Loss (gain) from sale of property and equipment			(1	)			(5	)			(1	)			-				(5	)
Change in employee benefit liabilities, net			(11	)			(40	)			(7	)			(32	)			(125	)
			9,818				9,828				4,670				4,205				15,678
Changes in asset and liability items:
Increase (decrease) in trade receivables, net			(6,755	)			2,696				(7,365	)			(3,610	)			7,835
Decrease (increase) in other accounts receivables			942				1,539				1,458				177				(1,150	)
Decrease (increase) in inventories			9,765				(11,452	)			5,634				(482	)			(19,694	)
Decrease (increase) in deferred expenses			239				3,042				127				(512	)			2,814
Increase (decrease) in trade payables			(5,092	)			(5,436	)			3,693				1,276				(8,885	)
Increase (decrease) in other accounts payables			(1,038	)			(408	)			1,013				(170	)			765
Increase (decrease) in deferred revenues			(121	)			3				1				(381	)			113
			(2,060	)			(10,016	)			4,561				(3,702	)			(18,202	)
Cash received (paid) during the period for:
Interest paid			(266	)			(744	)			(137	)			(403	)			(1,228	)
Interest received			788				25				508				-				-
Taxes paid			(88	)			(112	)			(65	)			(94	)			(217	)
			434				(831	)			306				(497	)			(1,445	)
Net cash provided by (used in) operating activities		$	14,983			$	(1,016	)		$	13,963			$	1,818			$	4,315

 

 

KAMADA LTD.

 

Condensed Consolidated Interim Statements of Cash Flows

 

		Six months period Ended								Three months period Ended								Year Ended
		June, 30								June, 30								December 31,
		2024				2023				2024				2023				2023
		Unaudited																Audited
		U.S Dollars In thousands
Cash Flows from Investing Activities
Purchase of property and equipment and intangible assets			(5,692	)			(2,147	)			(3,010	)			(1,030	)			(5,850	)
Proceeds from sale of property and equipment			1				6				1				(18	)			7
Net cash used in investing activities			(5,691	)			(2,141	)			(3,009	)			(1,048	)			(5,843	)
Cash Flows from Financing Activities
Proceeds from exercise of share base payments			2				3				1				2				4
Repayment of lease liabilities			(571	)			(517	)			(327	)			(246	)			(850	)
Repayment of long-term loans			-				(2,222	)			-				(1,111	)			(17,407	)
Proceeds from issuance of ordinary shares, net			-				-				-				-				58,231
Repayment of other long-term liabilities			(7,848	)			(6,000	)			(2,352	)			(4,500	)			(17,300	)
Net cash provided by (used in) financing activities			(8,417	)			(8,736	)			(2,678	)			(5,855	)			22,678
Exchange differences on balances of cash and cash equivalent			31				(577	)			77				(248	)			233
Increase (decrease) in cash and cash equivalents			906				(12,470	)			8,353				(5,333	)			21,383
Cash and cash equivalents at the beginning of the period			55,641				34,258				48,194				27,121				34,258
Cash and cash equivalents at the end of the period		$	56,547			$	21,788			$	56,547			$	21,788			$	55,641
Significant non-cash transactions
Right-of-use asset recognized with corresponding lease liability		$	521			$	3,585			$	215			$	5			$	6,546
Purchase of property and equipment and Intangible assets		$	272			$	840			$	272			$	840			$	646

 

NON-IFRS MEASURES

 

		Six months period ended								Three months period ended								Year ended
		June 30,								June 30,								December 31,
		2024				2023				2024				2023				2023
		In thousands
Net income		$	6,791			$	3			$	4,426			$	1,812			$	8,284
Taxes on income			137				106				63				93				145
Financial expense (income), net			2,751				2,811				1,151				726				1,635
Depreciation and amortization expense			6,466				6,327				3,229				3,204				12,714
Non-cash share-based compensation expenses			476				629				235				214				1,314
Adjusted EBITDA		$	16,621			$	9,876			$	9,104			$	6,049			$	24,092

 

 

Exhibit 99.2

 

August 2024 Q2 s& H1/2024 Investors Call

FORWARD - LOOKING STATEMENT This presentation is not intended to provide investment or medical advice. It should be noted that some products under develo pme nt described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical tr ial s. This presentation contains forward - looking statements, which express the current beliefs and expectations of Kamada’s management. Such statements include 2024 financial guidance; 5 - year growth strategy and plans for double digit growth; progression of inhaled AAT clinical study, its benefits and potential market size and potential FDA's feedback during H2/2024; success in being a pioneer in areas of li mit ed treatment alternatives; expansion to new markets, mainly MENA region; growth prospects, product introductions and revenue projections f or KedRAB , Cytogam , Israeli distribution business segment and U.S. plasma segment; success in identify and integrating M&A targets for growth. Th ese statements involve a number of known and unknown risks and uncertainties that could cause Kamada's future results, performance or achievements to differ significantly from the projected results, performances or achievements expressed or implied by such fo rwa rd - looking statements. Important factors that could cause or contribute to such differences include, but are not limited to, risks relat ing to Kamada's ability to successfully develop and commercialize its products and product candidates, progress and results of any clinical t ria ls, introduction of competing products, continued market acceptance of Kamada’s commercial products portfolio, impact of geo - political environment in the middle east, impact of any changes in regulation and legislation that could affect the pharmaceutical industry, difficulty in pr edicting, obtaining or maintaining U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, restrai ns related to third parties’ IP rights and changes in the health policies and structures of various countries, success of M&A strategies, e nvi ronmental risks, changes in the worldwide pharmaceutical industry and other factors that are discussed under the heading “Risk Factors” of Kamada’s 2023 Annual Report on Form 20 - F (filed on March 6, 2024), as well as in Kamada’s recent Forms 6 - K filed with the U.S. Securities and Exchange Commission. This presentation includes certain non - IFRS financial information, which is not intended to be considered in isolation or as a s ubstitute for, or superior to, the financial information prepared and presented in accordance with IFRS. The non - IFRS financial measures may be ca lculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. In accordance wi th the requirement of the SEC regulations a reconciliation of these non - IFRS financial measures to the comparable IFRS measures is incl uded in an appendix to this presentation. Management uses these non - IFRS financial measures for financial and operational decision - making a nd as a means to evaluate period - to - period comparisons. Management believes that these non - IFRS financial measures provide meaningful supplemental information regarding Kamada’s performance and liquidity. Forward - looking statements speak only as of the date they are made, and Kamada undertakes no obligation to update any forward - lo oking statement to reflect the impact of circumstances or events that arise after the date the forward - looking statement was made, exc ept as required by applicable law. 2

KEDRAB® CYTOGAM® HEPGAM B® VARIZIG® WINRHO® GLASSIA® KAMADA - A GROWING GLOBAL COMMERCIAL - STAGE BIOPHARMACEUTICAL COMPANY 6 FDA - Approved Products 16 % CAGR (from 2021) $ 158 - 162M 2024 Revenues Guidance $ 28 - 32M 2024 Adj. EBIDTA Guidance 4 Pillars of Growth LEADER IN SPECIALTY PLASMA THERAPIES, FOCUSED ON DISEASES WITH LIMITED TREATMENT ALTERNATIVES $ 56.6 M Cash (Q 2 / 2024 ) 3 Organic Growth M&A Transactions Inhaled AAT Pivotal Study Plasma Collection Centers

DELIVERING ON OUR COMMITMENTS 4

KAMADA ’ S ROADMAP FOR ANNUAL DOUBLE - DIGIT GROWTH 5 Organic Growth Portfolio of 6 FDA - approved products; Over 30 territories M&A Transactions Support growth through M&A transactions Plasma Collection Centers Each new collection center contributes annual revenues of $8M - $10M Inhaled AAT Phase III pivotal clinical study, targeting a market of over $2B

Q 2 – 24 CONTINUING THE GROWTH REVENUE Q 2 - 24 $42.5 Q 2 - 23 $ 37.4 13% NET INCOME Q 2 - 24 $ 4.4 Q 2 - 23 $1.8 144 % GROSS PROFIT Q 2 - 24 $19.0 Q 2 - 23 $ 14.4 31 % Adj. EBITDA Q 2 - 24 $ 9.1 Q 2 - 23 $6.0 51 % DOUBLE DIGIT INCREASE 6 For reconciliation of Adjusted EBITDA please refer to slide 23

7 REVENUE H 1 - 24 $80.2 H 1 - 23 $ 68.2 18 % NET INCOME H 1 - 24 $ 6.8 H 1 - 23 $0.0 n/a GROSS PROFIT H 1 - 24 $35.7 H 1 - 23 $ 26.3 36 % Adj. EBITDA H 1 - 24 $ 16.6 H 1 - 23 $9.9 68 % DOUBLE DIGIT INCREASE H 1 – 24 CONTINUING THE GROWTH For reconciliation of Adjusted EBITDA please refer to slide 23

6 18 24 28 - 32 2021 2022 2023 2024 104 129 143 158 – 162 2021 2022 2023 2024 ADJUSTED EBITDA US$M 2024 represents annual guidance 2024 represents annual guidance ANNUAL DOUBLE - DIGIT GROWTH TRAJECTORY REVENUES US$M 16 % CAGR 77 % CAGR H 1 ĔČ Ţ đČƱ š H 1 čē Ţ đēƱ š 8

9 6 FDA - APPROVED SPECIALTY PLASMA PRODUCTS KEDRAB® [Rabies Immune Globulin (Human)] Post exposure prophylaxis of rabies infection CYTOGAM® [Cytomegalovirus Immune Globulin (Human)] Prophylaxis of CMV disease associated with transplants HEPGAM B® [Hepatitis B Immune Globulin (Human)] Prevention of HBV recurrence following liver transplants VARIZIG® [Varicella Zoster Immune Globulin (Human)] Post - exposure prophylaxis of varicella in high - risk patients WINRHO® [Rho(D) Immune Globulin (Human)] Treatment of ITP & suppression of Rh isoimmunization (HDN) KEY FOCUS ON TRANSPLANTS & RARE CONDITIONS For Important Safety Information, visit www.Kamada.com GLASSIA® [Alpha 1 - Proteinase Inhibitor (Human)] Augmentation therapy for Alpha - 1 Antitrypsin Deficiency (AATD)

DISTRIBUTION SEGMENT GROWTH More than 25 products exclusively licensed from leading international pharmaceutical companies, marketed in the Israeli market EXCLUSIVE DISTRIBUTOR IN ISRAEL FOR LEADING BIOPHARMACEUTICAL COMPANIES Key areas : plasma - derived, respiratory, rare diseases, infectious diseases, biosimilar portfolio of 11 product candidates, mainly from Alvotech First biosimilar was launched in Q 1 / 2024 and second product expected to be launched by end of 2024 The other Biosimilar products are expected to be launched through 2028 , upon receipt of regulatory approval Biosimilar portfolio represents the main growth driver with estimated peak annual sales of $ 30 - 34 M 10

11 Exploring strategic business development opportunities to identify potential acquisition or in - licensing Focusing on products synergistic to our existing commercial and/or production activities Strong financial position and proven successful M&A capabilities M&A TRANSACTIONS SEEKING THE NEXT BREAKTHROUGH

12 Currently opening 2 additional centers: Houston, Texas ( H 2 - 24 ) San Antonio, Texas (H 1 - 25 ) Collecting hyper - immune plasma for our specialty IgG products and normal source plasma (NSP) to support revenue growth Average annual revenues of a mature collection center ranges from $ 8 M to $ 10 M KAMADA PLASMA EXPANDING VERTICAL INTEGRATION & REVENUE GROWTH

INHALED AAT PHASE 3 PIVOTAL STUDY Non - Invasive, at - home treatment. Expected better ease of use and quality of life for AATD patients than current IV SOC Most effective mode of treatment for delivering therapeutic amounts of AAT directly into the airways Studied in more than 200 individuals to date, with an established safety profile Only 1 / 8 th of the IV AAT dosing, more cost - effective; favorable market access landscape STUDY D ESIGN EXPECTED ADVANTAGES Ɗ čŃč Ɗ randomization; 9 active sites; ~ 45 % of patients enrolled to date; Open Label Extension (OLE) initiated Mid 2024 Inhaled AAT ĔČ mg Ɗ once Ɗ daily o r Ɗ placebo Ɗ during Ɗ two Ɗ years of Ɗ treatment Primary Ɗ Endpoint: Lung Ɗ function - FEV č Secondary Ɗ Endpoints Ń Lung Ɗ density - CT Ɗ densitometry Ɗ and Ɗ other Ɗ disease Ɗ severity Ɗ parameters 13 POTENTIAL TRANSFORMATIVE TREATMENT IN AATD - RELATED LUNG DISEASE

$ 2 Billion A substantial market opportunity ( 2028 ) Filed an IND amendment with revised statistical analysis plan and study protocol, expecting FDA feedback during H 2 / 2024 FDA recently reconfirmed overall study design, endorsed positive safety data to date, and expressed willingness to potentially accept a P< 0.1 alpha level in evaluating the trial ’ s efficacy primary endpoint INHALED AAT PHASE 3 PIVOTAL STUDY Global, double - blind, randomized, placebo - controlled pivotal Phase 3 clinical trial testing the safety and efficacy of inhaled AAT in patients with AATD. Study design meets FDA and EMA ’ s requirements Source: CantorFizgerald, JAN 11 2024 14

15 US $ M H1/24 H1/23 Q2/24 Q2/23 FY 2023 DETAILS PROPRIETARY 72.9 55.0 39.1 30.9 115.5 Driven by two key growth drivers, KEDRAB® & CYTOGAM® DISTRIBUTION 7.3 13.2 3.3 6.5 27.1 TOTAL REVENUES 80.2 68.2 42.5 37.4 142.5 18% YoY increase; H1 revenues - 50% of mid - point annual guidance GROSS PROFIT 35.7 26.3 19.0 14.4 55.5 GROSS MARGIN 45% 39% 45% 39% 39% 6 basis point increase YoY OPEX (26.0) (23.4) (13.3) (11.8) (45.4) NET PROFIT 6.8 0.0 4.4 1.8 8.3 Adjusted EBITDA 16.6 9.9 9.1 6.0 24.1 68% YoY increase; 21% of revenues & 55% of mid - point annual guidance CASH 56.5 21.8 55.6 TOTAL ASSETS 351.0 314.4 354.9 Including acquisition related intangible assets ($133M @ June 24) BANK LOAN 0.0 15.2 0.0 5 - year term loan paid down in full during Q3 - 23 LEASE LIABILITIES 8.6 6.0 8.8 Increase associated with new plasma collection centers in the U.S. CONTINGENT LIABILITIES 63.9 80.6 68.2 Acquisition related contingent consideration EQUITY 251.2 176.8 244.0 Increase mainly due to a $60M private placement with FIMI NET DEBT (15.9) (80.1) ( 21.4 ) Contingent and lease liabilities net of available cash Adjusted EBITDA is defined as net income, plus ( i ) tax expense, (ii) financial income (expense), net, (iii) depreciation and amortization ; and (v) non - cash share - based compensation expenses STRONG H 1 2024 FINANCIAL RESULTS

16 NON - IFRS MEASURES – ADJUSTED EBITDA US $ M H 1 / 24 H1/23 Q 2 / 24 Q2/23 2023 NET PROFIT 6.8 0.0 4.4 1.8 8.3 TAXES ON INCOME 0.1 0.1 0.1 0.1 0.1 REVALUATION OF ACQUISITION RELATED CONTINGENT CONSIDERATION 3.6 2.1 1.7 0.3 1.0 OTHER FINANCIAL EXPENSE, NET ( 0.8 ) 0.7 ( 0.6 ) 0.4 0.7 AMORTIZATION OF ACQUISITION RELATED INTANGIBLE ASSETS 3.5 3.5 1.8 1.8 7.1 OTHER DEPRECIATION AND AMORTIZATION EXPENSES 2.9 2.8 1.5 1.4 5.7 NON - CASH SHARE - BASED COMPENSATION EXPENSES 0.5 0.6 0.2 0.2 1.3 ADJUSTED EBITDA 16.6 9.9 9.1 6.0 24.1 Adjusted EBITDA is defined as net income, plus ( i ) tax expense, (ii) financial income (expense), net, (iii) depreciation and amortization ; and (v) non - cash share - based compensation expenses

KEDRAB® CYTOGAM® HEPGAM B® VARIZIG® WINRHO® GLASSIA® KAMADA – SIGNIFICANT UPSIDE POTENTIAL 6 FDA - Approved Products 16 % CAGR (from 2021 ) $ 158 - 162 M 2024 Revenues Guidance $28 - 32M 2024 Adj. EBIDTA Guidance 4 Pillars of Growth $ 56.6 M Cash (Q 2 / 2024 ) DELIVERING ON OUR COMMITMENTS 17 Organic Growth M&A Transactions Inhaled AAT Pivotal Study Plasma Collection Centers

THANK YOU www.kamada.com

v3.24.2.u1

Document And Entity Information	6 Months Ended
	Jun. 30, 2024
Document Information Line Items
Entity Registrant Name	Kamada Ltd.
Document Type	6-K
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001567529
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity File Number	001-35948

v3.24.2.u1

Condensed Consolidated Interim Statements of Financial Position - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023
Current Assets
Cash and cash equivalents	$ 56,547	$ 55,641	$ 21,788
Trade receivables, net	26,228	19,877	24,581
Other accounts receivables	4,940	5,965	3,077
Inventories	78,713	88,479	80,237
Total Current Assets	166,428	169,962	129,683
Non-Current Assets
Property, plant and equipment, net	31,971	28,224	26,936
Right-of-use assets	7,552	7,761	5,517
Intangible assets, Goodwill and other long-term assets	136,830	140,465	143,986
Contract assets	8,257	8,495	8,267
Total Non-Current Assets	184,610	184,945	184,706
Total Assets	351,038	354,907	314,389
Current Liabilities
Current maturities of bank loans			4,444
Current maturities of lease liabilities	1,494	1,384	1,063
Current maturities of other long term liabilities	12,610	14,996	25,077
Trade payables	19,532	24,804	27,969
Other accounts payables	7,233	8,261	7,235
Deferred revenues	27	148	38
Total Current Liabilities	40,896	49,593	65,826
Non-Current Liabilities
Bank loans			10,741
Lease liabilities	7,065	7,438	4,972
Contingent consideration	17,085	18,855	19,028
Other long-term liabilities	34,238	34,379	36,514
Employee benefit liabilities, net	602	621	556
Total Non-Current Liabilities	58,990	61,293	71,811
Shareholder’s Equity
Ordinary shares	15,023	15,021	11,737
Additional paid in capital net	266,313	265,848	210,727
Capital reserve due to translation to presentation currency	(3,490)	(3,490)	(3,490)
Capital reserve from hedges	(12)	140	(67)
Capital reserve from share-based payments	6,444	6,427	5,902
Capital reserve from employee benefits	283	275	424
Accumulated deficit	(33,409)	(40,200)	(48,481)
Total Shareholder’s Equity	251,152	244,021	176,752
Total Liabilities and Shareholder’s Equity	$ 351,038	$ 354,907	$ 314,389

v3.24.2.u1

Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Income Statement [Abstract]
Revenues from proprietary products	$ 39,146	$ 30,940	$ 72,904	$ 55,001	$ 115,458
Revenues from distribution	3,326	6,503	7,304	13,152	27,061
Total revenues	42,472	37,443	80,208	68,153	142,519
Cost of revenues from proprietary products	20,718	17,192	38,338	30,416	63,342
Cost of revenues from distribution	2,803	5,815	6,168	11,462	23,687
Total cost of revenues	23,521	23,007	44,506	41,878	87,029
Gross profit	18,951	14,436	35,702	26,275	55,490
Research and development expenses	4,803	4,283	9,098	7,514	13,933
Selling and marketing expenses	4,730	3,940	9,361	7,862	16,193
General and administrative expenses	3,778	3,484	7,564	6,902	14,381
Other expenses		98		1,077	919
Operating income (loss)	5,640	2,631	9,679	2,920	10,064
Financial income	508		788	25	588
Income (expenses) in respect of currency exchange differences and derivatives instruments, net	191	22	315	173	55
Financial Income (expense) in respect of contingent consideration and other long- term liabilities.	(1,705)	(309)	(3,550)	(2,070)	(980)
Financial expenses	(145)	(439)	(304)	(939)	(1,298)
Income (expense) before tax on income	4,489	1,905	6,928	109	8,429
Taxes on income	63	93	137	106	145
Net Income (loss)	4,426	1,812	6,791	3	8,284
Other Comprehensive Income (loss) :
Gain (loss) on cash flow hedges	(24)	(88)	(95)	(244)	(186)
Net amounts transferred to the statement of profit or loss for cash flow hedges		120	(57)	265	414
Items that will not be reclassified to profit or loss in subsequent periods:
Remeasurement gain (loss) from defined benefit plan	1	(115)	8	76	(73)
Total comprehensive income (loss)	$ 4,403	$ 1,729	$ 6,647	$ 100	$ 8,439
Earnings per share attributable to equity holders of the Company:
Basic net earnings per share (in Dollars per share)	$ 0.08	$ 0.04	$ 0.12	$ 0	$ 0.17
Diluted net earnings per share (in Dollars per share)	$ 0.08	$ 0.04	$ 0.12	$ 0	$ 0.15

v3.24.2.u1

Condensed Consolidated Interim Statements of Changes in Equity - USD ($) $ in Thousands	Share capital	Additional paid in capital	Capital reserve due to translation to presentation currency	Capital reserve from hedges	Capital reserve from sharebased payments	Capital reserve from employee benefits	Accumulated deficit	Total
Balance at Dec. 31, 2022	$ 11,734	$ 210,495	$ (3,490)	$ (88)	$ 5,505	$ 348	$ (48,484)	$ 176,020
Net income							3	3
Other comprehensive income (loss)				21		76		97
Total comprehensive income (loss)				21		76	3	100
Exercise and forfeiture of share-based payment into shares	3	232			(232)			3
Cost of share-based payment					629			629
Balance at Jun. 30, 2023	11,737	210,727	(3,490)	(67)	5,902	424	(48,481)	176,752
Balance at Dec. 31, 2022	11,734	210,495	(3,490)	(88)	5,505	348	(48,484)	176,020
Net income							8,284	8,284
Other comprehensive income (loss)				228		(73)		155
Total comprehensive income (loss)				228		(73)	8,284	8,439
Exercise and forfeiture of share-based payment into shares	4	405			(405)			4
Issuance of shares	3,283	54,948						58,231
Cost of share-based payment					1,327			1,327
Balance at Dec. 31, 2023	15,021	265,848	(3,490)	140	6,427	275	(40,200)	244,021
Balance at Mar. 31, 2023	11,736	210,665	(3,490)	(99)	5,750	539	(50,293)	174,808
Net income							1,812	1,812
Other comprehensive income (loss)				32		(115)		(83)
Total comprehensive income (loss)				32		(115)	1,812	1,729
Exercise and forfeiture of share-based payment into shares	1	62			(62)			1
Cost of share-based payment					214			214
Balance at Jun. 30, 2023	11,737	210,727	(3,490)	(67)	5,902	424	(48,481)	176,752
Balance at Dec. 31, 2023	15,021	265,848	(3,490)	140	6,427	275	(40,200)	244,021
Net income							6,791	6,791
Other comprehensive income (loss)				(152)		8		(144)
Total comprehensive income (loss)				(152)		8	6,791	6,647
Exercise and forfeiture of share-based payment into shares	2	465			(465)			2
Cost of share-based payment					482			482
Balance at Jun. 30, 2024	15,023	266,313	(3,490)	(12)	6,444	283	(33,409)	251,152
Balance at Mar. 31, 2024	15,022	266,183	(3,490)	12	6,336	282	(37,835)	246,510
Net income							4,426	4,426
Other comprehensive income (loss)				(24)		1		(23)
Total comprehensive income (loss)				(24)		1	4,426	4,403
Exercise and forfeiture of share-based payment into shares	1	130			(130)			1
Cost of share-based payment					238			238
Balance at Jun. 30, 2024	$ 15,023	$ 266,313	$ (3,490)	$ (12)	$ 6,444	$ 283	$ (33,409)	$ 251,152

v3.24.2.u1

Condensed Consolidated Interim Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Cash Flows from Operating Activities
Net income	$ 4,426	$ 1,812	$ 6,791	$ 3	$ 8,284
Adjustments to the profit or loss items:
Depreciation and impairment	3,229	3,204	6,466	6,327	12,714
Financial expenses (income), net	1,151	726	2,751	2,811	1,635
Cost of share-based payment	235	214	476	629	1,314
Taxes on income	63	93	137	106	145
Loss (gain) from sale of property and equipment	(1)		(1)	(5)	(5)
Change in employee benefit liabilities, net	(7)	(32)	(11)	(40)	(125)
Adjustments to the profit or loss items	4,670	4,205	9,818	9,828	15,678
Changes in asset and liability items:
Increase (decrease) in trade receivables, net	(7,365)	(3,610)	(6,755)	2,696	7,835
Decrease (increase) in other accounts receivables	1,458	177	942	1,539	(1,150)
Decrease (increase) in inventories	5,634	(482)	9,765	(11,452)	(19,694)
Decrease (increase) in deferred expenses	127	(512)	239	3,042	2,814
Increase (decrease) in trade payables	3,693	1,276	(5,092)	(5,436)	(8,885)
Increase (decrease) in other accounts payables	1,013	(170)	(1,038)	(408)	765
Increase (decrease) in deferred revenues	1	(381)	(121)	3	113
Total Changes in asset and liability	4,561	(3,702)	(2,060)	(10,016)	(18,202)
Cash received (paid) during the period for:
Interest paid	(137)	(403)	(266)	(744)	(1,228)
Interest received	508		788	25
Taxes paid	(65)	(94)	(88)	(112)	(217)
Cash received (paid) during the year	306	(497)	434	(831)	(1,445)
Net cash provided by (used in) operating activities	13,963	1,818	14,983	(1,016)	4,315
Cash Flows from Investing Activities
Purchase of property and equipment and intangible assets	(3,010)	(1,030)	(5,692)	(2,147)	(5,850)
Proceeds from sale of property and equipment	1	(18)	1	6	7
Net cash used in investing activities	(3,009)	(1,048)	(5,691)	(2,141)	(5,843)
Cash Flows from Financing Activities
Proceeds from exercise of share base payments	1	2	2	3	4
Repayment of lease liabilities	(327)	(246)	(571)	(517)	(850)
Repayment of long-term loans		(1,111)		(2,222)	(17,407)
Proceeds from issuance of ordinary shares, net					58,231
Repayment of other long-term liabilities	(2,352)	(4,500)	(7,848)	(6,000)	(17,300)
Net cash provided by (used in) financing activities	(2,678)	(5,855)	(8,417)	(8,736)	22,678
Exchange differences on balances of cash and cash equivalent	77	(248)	31	(577)	233
Increase (decrease) in cash and cash equivalents	8,353	(5,333)	906	(12,470)	21,383
Cash and cash equivalents at the beginning of the period	48,194	27,121	55,641	34,258	34,258
Cash and cash equivalents at the end of the period	56,547	21,788	56,547	21,788	55,641
Significant non-cash transactions
Right-of-use asset recognized with corresponding lease liability	215	5	521	3,585	6,546
Purchase of property and equipment and Intangible assets	$ 272	$ 840	$ 272	$ 840	$ 646

v3.24.2.u1

General	6 Months Ended
	Jun. 30, 2024
General [Abstract]
General	Note 1:- General   General description of the Company and its activity   Kamada Ltd. (the “Company”) is a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field focused on diseases of limited treatment alternatives. The Company is also advancing an innovative development pipeline targeting areas of significant unmet medical need. The Company’s strategy is focused on driving profitable growth from its significant commercial catalysts as well as its manufacturing and development expertise in the plasma-derived and biopharmaceutical fields. The Company’s commercial products portfolio includes six FDA approved plasma-derived biopharmaceutical products KEDRAB®, CYTOGAM®, VARIZIG®, WINRHO SDF®, HEPAGAM B® and GLASSIA®, as well as KAMRAB®, KAMRHO (D)® and two types of equine-based anti-snake venom (ASV) products. The Company distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Argentina, Brazil, India, Australia and other countries in Latin America, Europe, the Middle East and Asia. The Company leverages its expertise and presence in the Israeli market to distribute, for use in Israel, more than 25 pharmaceutical products that are supplied by international manufacturers and in addition have eleven biosimilar products in its Israeli distribution portfolio, which, subject to European Medicines Agency (EMA) and Israeli Ministry of Health (“IL MOH”) approvals, are expected to be launched in Israel through 2028. The Company owns an FDA licensed plasma collection center in Beaumont, Texas, which currently specializes in the collection of hyper-immune plasma used in the manufacture of KAMRHO (D), KAMRAB and KEDRAB. In addition to the Company’s commercial operation, it invests in research and development of new product candidates. The Company’s leading investigational product is an inhaled AAT for the treatment of AAT deficiency, for which it is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial.   In November 2021, the Company acquired CYTOGAM, WINRHO SDF, VARIZIG and HEPGAM B from Saol Therapeutics Ltd. (“Saol”). The acquisition of this portfolio furthered the Company’s core objective to become a fully integrated specialty plasma company with strong commercial capabilities in the U.S. market, as well as to expand to new markets, mainly in the Middle East/North Africa region, and to broaden the Company’s portfolio offering in existing markets. The Company’s wholly owned U.S. subsidiary, Kamada Inc., is responsible for the commercialization of the four products in the U.S. market, including direct sales to wholesalers and local distributers. Refer to Note 5 in our annual Financial report for further details on this acquisition.   The Company markets GLASSIA in the U.S. through a strategic partnership with Takeda Pharmaceuticals Company Limited (“Takeda”). Historically, the Company generated revenues on sales of GLASSIA, manufactured by the Company, to Takeda for further distribution in the United States. In accordance with the agreement with Takeda, the Company ceased the production and sale of GLASSIA to Takeda during 2021, and during the first quarter of 2022, Takeda began to pay the Company royalties on sales of GLASSIA manufactured by Takeda, at a rate of 12% on net sales through August 2025 and at a rate of 6% thereafter until 2040, with a minimum of $5 million annually for each of the years from 2022 to 2040. Refer to Note 18 in our annual Financial report for further details on the engagement with Takeda.   The Company’s ordinary shares are listed for trading on the Tel Aviv Stock Exchange and the NASDAQ Global Select Market.   FIMI Opportunity Funds (“FIMI”), the leading private equity firm in Israel beneficially owns approximately 38% of the Company’s outstanding ordinary shares and is a controlling shareholder of the Company; within the meaning of the Israeli Companies Law, 1999. Refer to Note 20 for further details and Item 7 within the Company annual reports on Form 20-F.

v3.24.2.u1

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Significant Accounting Policies [Abstract]
Significant Accounting Policies	Note 2:- Significant Accounting Policies     a. Basis of preparation of the interim consolidated financial statements:    The interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles for the preparation of financial statements for interim periods, as prescribed in IAS 34, “Interim Financial Reporting”.     b. Implementation of new accounting standards:     Amendment to IAS 1, Presentation of Financial Statements: Classification of Liabilities as Current or Non-Current and subsequent amendment: Non-Current Liabilities with Covenants   The Amendment, together with the subsequent amendment to IAS 1 (see hereunder) replaces certain requirements for classifying liabilities as current or non-current. According to the Amendment, a liability will be classified as non-current when the entity has the right to defer settlement for at least 12 months after the reporting period, and it “has substance” and is in existence at the end of the reporting period. According to the subsequent amendment, as published in October 2022, covenants with which the entity must comply after the reporting date do not affect classification of the liability as current or non-current. Additionally, the subsequent amendment adds disclosure requirements for liabilities subject to covenants within 12 months after the reporting date, such as disclosure regarding the nature of the covenants, the date they need to be complied with and facts and circumstances that indicate the entity may have difficulty complying with the covenants. Furthermore, the Amendment clarifies that the conversion option of a liability will affect its classification as current or non-current, other than when the conversion option is recognized as equity.   The Amendment and subsequent amendment are effective for reporting periods beginning on or after January 1, 2024 with earlier application being permitted. The Amendment and subsequent amendment are applicable retrospectively, including an amendment to comparative data.   As of June 30, 2024, the Company does not have impact on its financial statement.      IFRS 18, Presentation and Disclosure in Financial Statements   This standard replaces IAS 1, Presentation of Financial Statements. The purpose of the standard is to provide improved structure and content to the financial statements, particularly the income statement.   The standard includes new disclosure and presentation requirements that were taken from IAS 1, Presentation of Financial Statements, with small changes.   As part of the new disclosure requirements, companies will be required to present two subtotals in the income statement: operating profit and profit before financing and taxes. Furthermore, for most companies, the results in the income statements will be classified into three categories: operating profit, profit from investments and profit from financing.   In addition to the changes in the structure of the income statements, the standard also includes a requirement to provide separate disclosure in the financial statements regarding the use of management-defined performance measures (non-GAAP measures).   Furthermore, the standard adds specific guidance for aggregation and disaggregation of items in the financial statements and in the notes. The standard will encourage companies to avoid classifying items as ‘other’ (for example, other expenses), and using this classification will lead to additional disclosure requirements.   The standard is effective from annual reporting periods beginning on or after January 1, 2027 with earlier application being permitted.   The Company is examining the effects of the standard on its financial statements with no plans for early adoption.

v3.24.2.u1

Significant Events in the Reporting Period	6 Months Ended
	Jun. 30, 2024
Significant Events in the Reporting Period [Abstract]
Significant Events in the Reporting Period	Note 3:- Significant events in the reporting period   On February 29, 2024, the Company’s Board of Directors approved the grant of options to purchase up to 27,468 options to purchase ordinary shares of the Company under the 2011 Plan and the US Appendix.   The Company granted, out of the above mentioned, to employees and executive officers the following:   Under the Israeli Share Option Plan:     - 20,800 options to purchase the ordinary shares of the Company, at an exercise price of NIS 23.91 (USD 6.67) per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated at $48 thousands.   Under the US Appendix:     - 6,668 options to purchase the ordinary shares of the Company, at an exercise price of USD 6.62 per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated on the date of grant at $18 thousands.

v3.24.2.u1

Operating Segments	6 Months Ended
	Jun. 30, 2024
Operating Segments [Abstract]
Operating Segments	Note 4:- Operating Segments     a. General:   The company has two operating segments, as follows:   Proprietary Products - Development, manufacturing, sales and distribution of proprietary plasma-derived protein therapeutics.       Distribution - Distribute imported drug products in Israel, which are manufactured by third parties.     b. Reporting on operating segments:       Proprietary Products     Distribution     Total       U.S Dollars in thousands       Unaudited   Six months period ended June 30, 2024                   Revenues   $ 72,904     $ 7,304     $ 80,208   Gross profit   $ 34,566     $ 1,136     $ 35,702   Unallocated corporate expenses                     (26,023 ) Finance expenses, net                     (2,751 ) Income before taxes on income                   $ 6,928         Proprietary Products     Distribution     Total       U.S Dollars in thousands       Unaudited   Six months period ended June 30, 2023                   Revenues   $ 55,001     $ 13,152     $ 68,153   Gross profit   $ 24,585     $ 1,690     $ 26,275   Unallocated corporate expenses                     (23,355 ) Finance expenses, net                     (2,811 ) Income before taxes on income                   $ 109         Proprietary Products     Distribution     Total       U.S Dollars in thousands       Unaudited   Three  months period ended June 30, 2024                   Revenues   $ 39,146     $ 3,326     $ 42,472   Gross profit   $ 18,428     $ 523     $ 18,951   Unallocated corporate expenses                     (13,311 ) Finance expenses, net                     (1,151 ) Income before taxes on income                   $ 4,489         Proprietary Products     Distribution     Total       U.S Dollars in thousands       Unaudited   Three months period ended June 30, 2023                   Revenues   $ 30,940     $ 6,503     $ 37,443   Gross profit   $ 13,748     $ 688     $ 14,436   Unallocated corporate expenses                     (11,805 ) Finance expenses, net                     (726 ) Income before taxes on income                   $ 1,905         Proprietary Products     Distribution     Total       U.S Dollars in thousands       Audited   Year Ended December 31, 2023                   Revenues   $ 115,458     $ 27,061     $ 142,519   Gross profit   $ 52,116     $ 3,374     $ 55,490   Unallocated corporate expenses                     (45,426 ) Finance expenses, net                     (1,635 ) Income before taxes on income                   $ 8,429       c. Reporting on operating segments by geographic region:       Six months period ended June 30, 2024       Proprietary Products     Distribution     Total       U.S Dollars in thousands       Unaudited   Geographical markets                   U.S.A   $ 55,169     $ -     $ 55,169   Israel     3,557       7,304       10,861   Canada     5,765               5,765   Europe     1,678       -       1,678   Latin America     5,235       -       5,235   Asia     1,500       -       1,500   Others                             $ 72,904     $ 7,304     $ 80,208         Six months period ended June 30, 2023       Proprietary Products     Distribution     Total       U.S Dollars in thousands       Unaudited   Geographical markets                   U.S.A   $ 31,288     $ -     $ 31,288   Israel     2,101       13,152       15,252   Canada     5,568               5,568   Europe     3,550       -       3,550   Latin America     9,931       -       9,931   Asia     2,480       -       2,480   Others     83       -       83       $ 55,001     $ 13,152     $ 68,153         Three months period ended June 30, 2024       Proprietary Products     Distribution     Total       U.S Dollars in thousands       Unaudited   Geographical markets                   U.S.A   $ 29,320     $ -     $ 29,320   Israel     1,725       3,326       5,051   Canada     2,484               2,484   Europe     1432       -       1,432   Latin America     4,119       -       4,119   Asia     66       -       66   Others             -               $ 39,146     $ 3,326     $ 42,472         Three months period ended June 30, 2023       Proprietary Products     Distribution     Total       U.S Dollars in thousands       Unaudited   Geographical markets                   U.S.A   $ 17,690     $ -     $ 17,690   Israel     1,107       6,503       7,610   Canada     2,336               2,336   Europe     216       -       216   Latin America     8,615       -       8,615   Asia     930       -       930   Others     46       -       46       $ 30,940     $ 6,503     $ 37,443         Year ended December 31, 2023       Proprietary Products     Distribution     Total       U.S Dollars in thousands       Audited   Geographical markets                   U.S.A   $ 73,741     $ -     $ 73,741   Israel     4,236       27,061       31,296   Canada     11,162       -       11,162   Europe     7,088       -       7,088   Latin America     12,928       -       12,928   Asia     6,147       -       6,147   Others     156       -       157       $ 115,458     $ 27,061     $ 142,519

v3.24.2.u1

Financial Instruments	6 Months Ended
	Jun. 30, 2024
Financial Instruments [Abstract]
Financial Instruments	Note 5:- Financial Instruments     a. Classification of financial instruments by fair value hierarchy   Financial assets (liabilities) measured at fair value        Level 1     Level 2     Level 3       U.S Dollars in thousands   June 30, 2024                   Derivatives instruments   $              -     $ (12 )   $ -   Contingent consideration     -       -       (19,928 )                           June 30, 2023                         Derivatives instruments     -       (72 )         Contingent consideration   $ -     $       $ (21,712 )                           December 31, 2023                         Derivatives instruments   $ -     $ 149     $ -   Contingent consideration   $ -     $ -     $ (21,855 )   During the three months ended on June 30, 2024 there were no transfers due to the fair value measurement of any financial instrument from Level 1 to Level 2, and furthermore, there were no transfers to or from Level 3 due to the fair value measurement of any financial instrument.

v3.24.2.u1

Subsequent Events	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
Subsequent events	Note 6:- Subsequent events    On July 21, 2024, the Company’s Board of Directors approved the grant of 15,081 options to purchase the ordinary shares of the Company , under the 2011 Plan and the US Appendix.   Under the Israeli Share Option Plan:     - 9,049 options to purchase the ordinary shares of the Company, at an exercise price of NIS 22.01 (USD 6.06) per share. The fair value of the options was estimated on the date of grant was estimated at $25 thousands   Under the US Appendix:     - 6,032 options to purchase the ordinary shares of the Company, at an exercise price of USD 6.07 per share. The fair value of the options was estimated on the date of grant was estimated at $15 thousands

v3.24.2.u1

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of preparation of the interim consolidated financial statements	a. Basis of preparation of the interim consolidated financial statements: The interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles for the preparation of financial statements for interim periods, as prescribed in IAS 34, “Interim Financial Reporting”.
Implementation of new accounting standards	b. Implementation of new accounting standards:   Amendment to IAS 1, Presentation of Financial Statements: Classification of Liabilities as Current or Non-Current and subsequent amendment: Non-Current Liabilities with Covenants The Amendment, together with the subsequent amendment to IAS 1 (see hereunder) replaces certain requirements for classifying liabilities as current or non-current. According to the Amendment, a liability will be classified as non-current when the entity has the right to defer settlement for at least 12 months after the reporting period, and it “has substance” and is in existence at the end of the reporting period. According to the subsequent amendment, as published in October 2022, covenants with which the entity must comply after the reporting date do not affect classification of the liability as current or non-current. Additionally, the subsequent amendment adds disclosure requirements for liabilities subject to covenants within 12 months after the reporting date, such as disclosure regarding the nature of the covenants, the date they need to be complied with and facts and circumstances that indicate the entity may have difficulty complying with the covenants. Furthermore, the Amendment clarifies that the conversion option of a liability will affect its classification as current or non-current, other than when the conversion option is recognized as equity. The Amendment and subsequent amendment are effective for reporting periods beginning on or after January 1, 2024 with earlier application being permitted. The Amendment and subsequent amendment are applicable retrospectively, including an amendment to comparative data. As of June 30, 2024, the Company does not have impact on its financial statement.   IFRS 18, Presentation and Disclosure in Financial Statements This standard replaces IAS 1, Presentation of Financial Statements. The purpose of the standard is to provide improved structure and content to the financial statements, particularly the income statement. The standard includes new disclosure and presentation requirements that were taken from IAS 1, Presentation of Financial Statements, with small changes. As part of the new disclosure requirements, companies will be required to present two subtotals in the income statement: operating profit and profit before financing and taxes. Furthermore, for most companies, the results in the income statements will be classified into three categories: operating profit, profit from investments and profit from financing. In addition to the changes in the structure of the income statements, the standard also includes a requirement to provide separate disclosure in the financial statements regarding the use of management-defined performance measures (non-GAAP measures). Furthermore, the standard adds specific guidance for aggregation and disaggregation of items in the financial statements and in the notes. The standard will encourage companies to avoid classifying items as ‘other’ (for example, other expenses), and using this classification will lead to additional disclosure requirements. The standard is effective from annual reporting periods beginning on or after January 1, 2027 with earlier application being permitted. The Company is examining the effects of the standard on its financial statements with no plans for early adoption.

v3.24.2.u1

Operating Segments (Tables)	6 Months Ended
	Jun. 30, 2024
Operating Segments [Abstract]
Schedule of Reporting on Operating Segments	Reporting on operating segments:     Proprietary Products     Distribution     Total       U.S Dollars in thousands       Unaudited   Six months period ended June 30, 2024                   Revenues   $ 72,904     $ 7,304     $ 80,208   Gross profit   $ 34,566     $ 1,136     $ 35,702   Unallocated corporate expenses                     (26,023 ) Finance expenses, net                     (2,751 ) Income before taxes on income                   $ 6,928       Proprietary Products     Distribution     Total       U.S Dollars in thousands       Unaudited   Six months period ended June 30, 2023                   Revenues   $ 55,001     $ 13,152     $ 68,153   Gross profit   $ 24,585     $ 1,690     $ 26,275   Unallocated corporate expenses                     (23,355 ) Finance expenses, net                     (2,811 ) Income before taxes on income                   $ 109       Proprietary Products     Distribution     Total       U.S Dollars in thousands       Unaudited   Three  months period ended June 30, 2024                   Revenues   $ 39,146     $ 3,326     $ 42,472   Gross profit   $ 18,428     $ 523     $ 18,951   Unallocated corporate expenses                     (13,311 ) Finance expenses, net                     (1,151 ) Income before taxes on income                   $ 4,489       Proprietary Products     Distribution     Total       U.S Dollars in thousands       Unaudited   Three months period ended June 30, 2023                   Revenues   $ 30,940     $ 6,503     $ 37,443   Gross profit   $ 13,748     $ 688     $ 14,436   Unallocated corporate expenses                     (11,805 ) Finance expenses, net                     (726 ) Income before taxes on income                   $ 1,905         Proprietary Products     Distribution     Total       U.S Dollars in thousands       Audited   Year Ended December 31, 2023                   Revenues   $ 115,458     $ 27,061     $ 142,519   Gross profit   $ 52,116     $ 3,374     $ 55,490   Unallocated corporate expenses                     (45,426 ) Finance expenses, net                     (1,635 ) Income before taxes on income                   $ 8,429
Schedule of Reporting on Operating Segments Geographic Region	Reporting on operating segments by geographic region:     Six months period ended June 30, 2024       Proprietary Products     Distribution     Total       U.S Dollars in thousands       Unaudited   Geographical markets                   U.S.A   $ 55,169     $ -     $ 55,169   Israel     3,557       7,304       10,861   Canada     5,765               5,765   Europe     1,678       -       1,678   Latin America     5,235       -       5,235   Asia     1,500       -       1,500   Others                             $ 72,904     $ 7,304     $ 80,208       Six months period ended June 30, 2023       Proprietary Products     Distribution     Total       U.S Dollars in thousands       Unaudited   Geographical markets                   U.S.A   $ 31,288     $ -     $ 31,288   Israel     2,101       13,152       15,252   Canada     5,568               5,568   Europe     3,550       -       3,550   Latin America     9,931       -       9,931   Asia     2,480       -       2,480   Others     83       -       83       $ 55,001     $ 13,152     $ 68,153         Three months period ended June 30, 2024       Proprietary Products     Distribution     Total       U.S Dollars in thousands       Unaudited   Geographical markets                   U.S.A   $ 29,320     $ -     $ 29,320   Israel     1,725       3,326       5,051   Canada     2,484               2,484   Europe     1432       -       1,432   Latin America     4,119       -       4,119   Asia     66       -       66   Others             -               $ 39,146     $ 3,326     $ 42,472       Three months period ended June 30, 2023       Proprietary Products     Distribution     Total       U.S Dollars in thousands       Unaudited   Geographical markets                   U.S.A   $ 17,690     $ -     $ 17,690   Israel     1,107       6,503       7,610   Canada     2,336               2,336   Europe     216       -       216   Latin America     8,615       -       8,615   Asia     930       -       930   Others     46       -       46       $ 30,940     $ 6,503     $ 37,443       Year ended December 31, 2023       Proprietary Products     Distribution     Total       U.S Dollars in thousands       Audited   Geographical markets                   U.S.A   $ 73,741     $ -     $ 73,741   Israel     4,236       27,061       31,296   Canada     11,162       -       11,162   Europe     7,088       -       7,088   Latin America     12,928       -       12,928   Asia     6,147       -       6,147   Others     156       -       157       $ 115,458     $ 27,061     $ 142,519

v3.24.2.u1

Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2024
Financial Instruments [Abstract]
Schedule of Financial Assets (Liabilities) Measured at Fair Value	Financial assets (liabilities) measured at fair value     Level 1     Level 2     Level 3       U.S Dollars in thousands   June 30, 2024                   Derivatives instruments   $              -     $ (12 )   $ -   Contingent consideration     -       -       (19,928 )                           June 30, 2023                         Derivatives instruments     -       (72 )         Contingent consideration   $ -     $       $ (21,712 )                           December 31, 2023                         Derivatives instruments   $ -     $ 149     $ -   Contingent consideration   $ -     $ -     $ (21,855 )

v3.24.2.u1

General (Details) $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($)
General [Line Items]
Interest rate	12.00%
Annual amount (in Dollars)	$ 5
Percentage of outstanding ordinary shares	38.00%
Takeda Pharmaceuticals Company Limited [Member]
General [Line Items]
Interest rate	6.00%

v3.24.2.u1

Significant Events in the Reporting Period (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) ₪ / shares shares	Feb. 29, 2024 shares
Significant Events in the Reporting Period [Line Items]
Option granted | shares	6,668	6,668
Exercise price per share | $ / shares	$ 6.62
Fair value of options (in Dollars) | $	$ 18	$ 18
Board of Directors [Member]
Significant Events in the Reporting Period [Line Items]
Option granted | shares			27,468
Israeli Share Option Plan [Member]
Significant Events in the Reporting Period [Line Items]
Option granted | shares	20,800	20,800
Exercise price per share | (per share)	$ 6.67	$ 23.91
Fair value of options (in Dollars) | $	$ 25	$ 25
Israeli Share Option Plan [Member] | Board of Directors [Member]
Significant Events in the Reporting Period [Line Items]
Fair value of options (in Dollars) | $	$ 48	$ 48

v3.24.2.u1

Operating Segments (Details)	6 Months Ended
	Jun. 30, 2024 segments
Operating Segments [Abstract]
Number of operating segments	2

v3.24.2.u1

Operating Segments (Details) - Schedule of Reporting on Operating Segments - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Schedule of Reporting on Operating Segments [Line Items]
Revenues	$ 42,472	$ 37,443	$ 80,208	$ 68,153	$ 142,519
Gross profit	18,951	14,436	35,702	26,275	55,490
Unallocated corporate expenses	(13,311)	(11,805)	(26,023)	(23,355)	(45,426)
Finance expenses, net	(1,151)	(726)	(2,751)	(2,811)	(1,635)
Income before taxes on income	4,489	1,905	6,928	109	8,429
Reportable Segments [Member] | Proprietary Products [Member]
Schedule of Reporting on Operating Segments [Line Items]
Revenues	39,146	30,940	72,904	55,001	115,458
Gross profit	18,428	13,748	34,566	24,585	52,116
Reportable Segments [Member] | Distribution [Member]
Schedule of Reporting on Operating Segments [Line Items]
Revenues	3,326	6,503	7,304	13,152	27,061
Gross profit	$ 523	$ 688	$ 1,136	$ 1,690	$ 3,374

v3.24.2.u1

Operating Segments (Details) - Schedule of Reporting on Operating Segments Geographic Region - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Geographical markets
Proprietary Products	$ 39,146	$ 30,940	$ 72,904	$ 55,001	$ 115,458
Distribution	3,326	6,503	7,304	13,152	27,061
Total	42,472	37,443	80,208	68,153	142,519
U.S.A [Member]
Geographical markets
Total	29,320	17,690	55,169	31,288	73,741
Israel [Member]
Geographical markets
Total	5,051	7,610	10,861	15,252	31,296
Canada [Member]
Geographical markets
Total	2,484	2,336	5,765	5,568	11,162
Europe [Member]
Geographical markets
Total	1,432	216	1,678	3,550	7,088
Latin America [Member]
Geographical markets
Total	4,119	8,615	5,235	9,931	12,928
Asia [Member]
Geographical markets
Total	66	930	1,500	2,480	6,147
Others [Member]
Geographical markets
Total		46		83	157
Proprietary Products [Member]
Geographical markets
Proprietary Products	39,146	30,940	72,904	55,001	115,458
Proprietary Products [Member] | U.S.A [Member]
Geographical markets
Proprietary Products	29,320	17,690	55,169	31,288	73,741
Proprietary Products [Member] | Israel [Member]
Geographical markets
Proprietary Products	1,725	1,107	3,557	2,101	4,236
Proprietary Products [Member] | Canada [Member]
Geographical markets
Proprietary Products	2,484	2,336	5,765	5,568	11,162
Proprietary Products [Member] | Europe [Member]
Geographical markets
Proprietary Products	1,432	216	1,678	3,550	7,088
Proprietary Products [Member] | Latin America [Member]
Geographical markets
Proprietary Products	4,119	8,615	5,235	9,931	12,928
Proprietary Products [Member] | Asia [Member]
Geographical markets
Proprietary Products	66	930	1,500	2,480	6,147
Proprietary Products [Member] | Others [Member]
Geographical markets
Proprietary Products		46		83	156
Distribution [Member]
Geographical markets
Distribution	3,326	6,503	7,304	13,152	27,061
Distribution [Member] | U.S.A [Member]
Geographical markets
Distribution
Distribution [Member] | Israel [Member]
Geographical markets
Distribution	3,326	6,503	7,304	13,152	27,061
Distribution [Member] | Canada [Member]
Geographical markets
Distribution
Distribution [Member] | Europe [Member]
Geographical markets
Distribution
Distribution [Member] | Latin America [Member]
Geographical markets
Distribution
Distribution [Member] | Asia [Member]
Geographical markets
Distribution
Distribution [Member] | Others [Member]
Geographical markets
Distribution

v3.24.2.u1

Financial Instruments (Details) - Schedule of Financial Assets (Liabilities) Measured at Fair Value - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023
Level 1 [Member]
Schedule of Financial Assets (Liabilities) Measured at Fair Value [Line Items]
Derivatives instruments
Contingent consideration
Level 2 [Member]
Schedule of Financial Assets (Liabilities) Measured at Fair Value [Line Items]
Derivatives instruments	(12)	149	(72)
Contingent consideration
Level 3 [Member]
Schedule of Financial Assets (Liabilities) Measured at Fair Value [Line Items]
Derivatives instruments
Contingent consideration	$ (19,928)	$ (21,855)	$ (21,712)

v3.24.2.u1

Subsequent Events (Details) $ / shares in Units, $ in Thousands		6 Months Ended
	Jul. 21, 2024 shares	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) ₪ / shares shares
Subsequent Events (Details) [Line Items]
Fair value options grant (in Dollars) | $		$ 18	$ 18
Subsequent Events [Member]
Subsequent Events (Details) [Line Items]
Share option purchase | shares	15,081
Israeli Share Option Plan [Member]
Subsequent Events (Details) [Line Items]
Share option purchase | shares		9,049	9,049
Exercise price, per share | (per share)		$ 6.06	$ 22.01
Fair value options grant (in Dollars) | $		$ 25	$ 25
US Appendix [Member]
Subsequent Events (Details) [Line Items]
Share option purchase | shares		6,032	6,032
Exercise price, per share | $ / shares		$ 6.07
Fair value options grant (in Dollars) | $		$ 15	$ 15

---